InfuSystem Holdings, Inc.
Shareholder Presentation
December 1, 2014
Exhibit 99.1


Safe Harbor Statement
Certain statements contained in this presentation are forward-looking statements and are based on future
expectations, plans and prospects for the business and operations of InfuSystem Holdings, Inc. (“InfuSystem”
or “the Company”) that involve a number of risks and uncertainties.  In connection with the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors
that could cause actual results to materially differ from those indicated by these forward-looking statements.
Those factors, risks and uncertainties include, but are not limited to: potential changes in overall healthcare
reimbursement, including CMS competitive bidding; sequestration; concentration of customers; increased
focus on early detection of cancer; competitive treatments; dependency on Medicare Supplier Number;
availability of chemotherapy drugs; global financial conditions; changes and enforcement of state and federal
laws; dependency on suppliers; risks associated with acquisitions and joint ventures, including integration
risks; US Healthcare Reform; relationships with healthcare professionals and organizations; technological
changes related to infusion therapy; [dependency on websites and intellectual property; dependency on key
personnel; dependency on banking relationships; risks associated with our common stock, as well as any
litigation to which the Company may be subject from time to time; and other risk factors as discussed in the
Company’s annual report on Form 10-K for the year ended December 31, 2013 and in subsequent  filings
made by the Company from time to time with the Securities and Exchange Commission (the “SEC”), which can
be obtained via the SEC’s Edgar website or by contacting the Company or the SEC.  Forward-looking
statements in this presentation are made as of December 1, 2014, and, unless required by law, the Company
disclaims any duty to supplement, update or revise such statements, whether as a result of subsequent
developments, changed expectations or otherwise.  The Company regularly posts important information to
the investors section of its website. 


Summary
InfuSystem is a growing healthcare company that
provides infusion pumps and related products and
services for patients in the home, in oncology clinics,
ambulatory surgery centers, and other sites of care
from five locations serving all 50 States and
Canada.
We deliver improved patient satisfaction
and outcomes with world-class quality, both in and
out of the home environment.
The company's
market share and profitable growth is predicated on
expansion into new therapies, increased use of
electronic connectivity, development of new
products and services, and strategic geographic
expansion.
Confidential Information of InfuSystem Holdings, Inc.
3


InfuSystem -
“Infusion Made Easy”
9 mos YTD September 30, 2014
(1)
Revenues $50.2M (Up 11%)
AEBITDA $11.5M (Up 2%)
Market Cap  $64.0M @ $2.87 (as of
11/20/14)
Company Overview
Provides infusion pumps and related
products and services for patients in:
The Patient’s Home
Oncology Clinics
Ambulatory Surgery Centers
And Other Sites of Care
Serves all 50 States & Canada
from 5 locations
Improves outcomes  and delivers high 
patient satisfaction with world-class ISO
and CHAP accredited quality
Profitable growth is predicated on:
Growth of oncology and orthopedic
surgery
Increased electronic connectivity
New products and services
Strategic geographic expansion
(1) Free Cash Flow = Adjusted EBITDA less CapEx and Purchases of
Medical Equipment
“The right pump, the right place, and the right time. 
Working and patient ready.”


InfuSystem
Manufacturer,
Rental
Companies
Insurance
Company
InfuSystem
Clinic
Patient
InfuSystem
Clinic, Hospital,
Home Infusion
Sales &
Sales &
Rental
Rental
revenue
revenue
via 3
via 3
revenue
revenue
streams.
streams.
Patient
Co-pay &
Deductible


Revenue Diversification
2009 Revenues $39M
2014 Revenues (Annualized 9m)
70%
26%
1%
1%
2%
48%
23%
12%
4%
12%
Rentals -
Colorectal Cancer
Rentals -
Other Cancers
Rentals -
Infectious Disease
Rentals -
Pain Management
Rentals -
Hospitals/Home Care
Rentals -
Service & Repair
Sales -
Equip, Consumables


InfuSystem Provider Niche –
Therapy Started in 
Clinic
Total
Total
Home
Home
Infusion
Infusion
Market
Market
Chemotherapy at Home
InfuSystem is the market
leader with over 1,600
practice sites served
Estimated over $200 M
market.
Cancer rates growing
Nerve Block at Home
5.69M orthopedic 
surgeries annually
50% are projected to be
Continuous Peripheral
Nerve Block Candidates
Estimated $700 M
market
Growing therapy


Electronic Connectivity through Electronic
Medical Record (EMR) Interface
Electronic
Data
Exchange
Interface Effects
Fuels market share
gains
Efficiency advantage
vs smaller players
Greater revenue per
employee
Greater customer
satisfaction


Lifecycle Management –
Infusion Pumps
Total Pump Fleet Management
Online, Anytime
Order New Pumps
Schedule Service & Repair
Access Recertification Docs


Lifecycle Management –
Asset Tracking
Smart Metrics
Loss Threat Count
11
Loss Threat Percent
3%
Assets Under Par
7
30 Day Average Daily Check-Outs
6


High Patient Satisfaction Scores


For Faster Turnaround and Improved Utilization
Kansas City
Service Center
Madison Heights
Service Center
Future Northeast
Service Center
Future Southeast
Service Center
Los Angeles Area
Service Center
Houston
Service Center
Toronto Canada
Service Center
InfuSystem Distribution
Reduced cost of air
shipments
Improved
utilization of pumps
Increased market
share of same-day
rental market


New Products & Services
Pain Management Service
Catheter care kits
Pole-mounted pump sales
and rentals in oncology
Smart Pump Services
Infusion disposals including
IV administration sets &
chemo safety


Financial Overview
Adjusted EBITDA (1)
Revenues
Free Cash Flow (1)
Basic EPS
(1) Free Cash Flow = Adjusted EBITDA less CapEx and Net Purchases of Medical Equipment
$38,964
$47,229
$54,637
$58,828
$62,280
$67,404
$30m
$40m
$50m
$60m
$70m
FY2009
FY2010
FY2011
FY2012
FY2013
LTM 3Q14
Revenues
Growing
$10,256
$13,126
$15,962
AEBITDA
Growing
$16,153
$6m
$10m
$14m
$18m
FY2011
FY2012
FY2013
LTM 3Q14
(1) Per 8K filed 3/28/13 for yrs 2011 and 2012
$5,754
$10,568
$11,839
$12,604
$4m
$8m
$12m
$16m
FY2011
FY2012
FY2013
LTM 3Q14
FCF
Growing
(4)
(4)
(5)
(4)
(3)
(2)
(1)
5
1Q
2Q
3Q
4Q
1Q
2Q
3Q
4Q
1Q
2Q
3Q
FY 2012
FY 2013
FY 2014
EPS Profitable &
Growing


Uses of Free Cash Flow
Every $1.00 invested in the rental fleet
returns ~$1.50 in revenue every year
for the life of the pump
Total Debt
PP&E and Medical Equipment in Service (at cost)
Unrestricted Liquidity
Medical Equipment Turnover Ratio


Positioned For Growth
Market Trends
InfuSystem is uniquely
positioned to take efficient
advantage of growing
market trends in…
Oncology
Orthopedic surgery
Growth of home infusion
Leadership
Experienced Medical
Industry Executives
Focused on improving
patient satisfaction and
outcomes
Supported by World Class  -
ISO and CHAPS Accredited  -
facilities and motivated
employee
Strategy
Increased use of electronic
connectivity
Expanding geographic
footprint
Expanding into new
therapies, products and
services


Where Does This Take INFU?
Aging Population and Cancer Growth
More Patients Home IV , Commercial Pay
Recognizing Value, CMS Competitive Bidding
Peripheral Nerve Block and Smart Pump Growth
Revenue Growth in High Single Digits Through 2015


Thank You for Your Interest!
IR Contact Info:
The Dilenschneider Group
212-922-0900
Rob Swadosh, rswadosh@dgi-nyc.com


Appendix: INFU Overview


Increasing Therapy Offerings to Payors
Payor
Surgery
Infectious
Disease
Oncology
Special
Disease
States


Full Line Multi-Therapy & Multi-Point Offering
HOW we provide TPP/DP/Service Pumps
Device & Pharma
Manufacturer,
Distributor, GPO, ACO
Partners
Provider
Patient
Payor


InfuSystem Niche –
Extension of Clinic to Home
25-year old business model in
DME billing
At home, at work, at play, all
while receiving the drug
High satisfaction scores
24/7 on-call oncology nurses
Proven outcomes with
continuous home infusion
Oncology, Post Surgical Pain,
Special Disease States
Bills patient insurance
250+ Commercial and
Government Payor
Contracts
Commercial Payors
reimburse more
therapies than CMS
Awarded contracts in
all 9
MSAs (1 of 3
National Vendors)
Average cuts of ~21%
for our category, per
CMS ($250,000 per yr)
Ambulatory Home Infusion
TPP Payor Contracts


Rentals, Sales & Service to Providers
Pump Experts
Direct sales, rental, and
lease of device and
supplies in US and
Canada
Pump Broker Expertise –
ability to acquire and
dispose of CAP EX in cost
effective way
Asset management,
rental and lease
Annual Pump
Recertification
Preventative
Maintenance
Warranty
World-Class ISO Certified
service facilities
Regional Distribution
West, South, East &
Canada
28+ Certified Technicians
Pump Rentals, Sales and
Asset Management
Preventative Maint.
Repair


Offering Infusion to All Points of Care
Provider
Oncology
Acute
Care
Emergency
Services
Long Term
Care
Home
Infusion


Compelling Value Proposition
In-House Service & Repairs
Convenience & Flexibility
Pre-Owned Equipment Expertise
One-Stop Shopping Solution
Convenience and flexibility of rentals and
financing minimize customer capital outlays
Rental and financing eliminates the need for       
in-house maintenance/service
Option to own, rent or finance –
designed to fit
customers’
operating and financial parameters
Shorter and longer-term financing options
One-stop shopping solution for ambulatory large
volume pump and other movable medical devices
Sales
Rentals
Supplies
Service
Financing
World-class biomedical repair and
service for pumps, defibrillators and
most other general medical
equipment
Allows InfuSystem to purchase, clean,
repair and certify any used medical
equipment the Company buys for
subsequent sale, rental or financing to
customers
Complementary core competencies allow InfuSystem to offer superior selection, flexibility, pricing and services
“ONE-STOP SHOP”
SERVICE &
REPAIRS
CONVENIENCE &
FLEXIBILITY
PRE-OWNED
EQUIPMENT
EXPERTISE
Unique ability to source and deploy pre-
owned movable medical equipment
Consistent, fair and knowledgeable
market maker for pre-owned pump
disposals
Market knowledge results in attractive
equipment acquisition costs


Payor & Customer Mix
Leading Cancer Institution Customers
Revenue by Payor (FY2013)
High diversification of providers and payors
No single healthcare provider represents more than 7% of Third-Party Payor revenues
Strong payor mix among Medicare, other commercial insurers, Blue Cross/Blue Shield, and Medicaid
Approximately 6% of revenues received directly from patients through co-pays or otherwise
Broad coverage further diversifies revenue streams
InfuSystem has strong relationships with the largest third-party payors and the leading cancer institutions
9 of 10 of the Top
Ten Cancer
Treatment Centers
CMS: Centers for Medicare and Medicaid Services
Medicare and
Medicaid
38%
BCBS
17%
Patient
6%
Commercial
39%


Infusion pumps
Enteral pumps
Direct Payor Business Model
Service & Repair
Products
InfuSystem sells, rents and finances a wide variety of new
and used large volume and ambulatory pumps
InfuSystem services and repairs both its own fleet of
pumps and many types of other movable medical
equipment
Syringe pumps
Ambulatory pumps
Large volume pumps
Ambulatory pumps
Fluid collection
Medical equipment
InfuSystem’s Direct Payor business is focused primarily on the sale, rental, financing and accompanying service of
movable
medical
equipment
to
hospitals
and
alternate
care
sites
who
pay
InfuSystem
directly
no
third-party
reimbursement
Founded in 1998 and headquartered in Olathe, KS with distribution/service centers in Santa Fe Springs, CA and
Mississauga, Ontario
InfuSystem services –
ISO 9001 -
and repairs movable medical equipment
Leading provider to alternate site healthcare facilities and hospitals in the United States and Canada
Home infusion providers, long-term care, physician clinics, research facilities, etc.
Transacts
directly
with
healthcare
providers
no
third-party
reimbursement
revenue


InfuSystem offers new pumps from top brands
Broker-dealer trading desk
In addition, over 70 models and versions of pre-owned pumps
are offered
Pre-owned pumps are re-built and certified by in-house
biomedical technicians to be patient ready
Warranty offered on pre-owned pumps
A variety of financing options to fit customers’
operating,
budgeting and financing parameters
Nationwide, industry-leading ISO 9001 service programs
Launching branch service center in Houston
Direct Payor Offerings
Pre-Owned & New Pumps from Top Manufacturers
Full Spectrum of Ownership Options for Customers
Sales
Rental
Asset Management
Renting new or pre-owned equipment
Rent pumps by the day, week or month to
match swings in patient count
Free shipping on all rentals
Industry leader in sales of pre-owned
equipment, creating significant savings
Competitive pricing on new equipment
Option to sell back pre-owned pumps
Leasing plans offered
ISO 9001 Service offered
Service plans offered
Local service expansion
2 existing; 1 planned
Coordinate with TPP
Loaner pumps available
Leading Provider of New and Pre-Owned Pumps


Medical Equipment Service & Repair
In addition to supporting and repairing
InfuSystem’s in-house fleet, the Company certifies,
recalibrates, repairs and services a variety of
infusion pumps
Pumps require scheduled maintenance and
calibration in accordance with manufacturer’s
specifications and regulatory guidelines
Service and repair capabilities on high demand
services reaching end of life that are no longer
supported by manufacturers
ISO certification and an established quality system
strengthens relationships with major customers
Provides InfuSystem an opportunity to establish a
business relationship with customers that acquired
pumps through other sources
Continuing and increased need for compliance
with current as well as anticipated regulations
28 highly qualified service technicians
5 major manufacturer relationships:
3 service centers, located in California,
Toronto and Kansas


Competitive Bidding Overview
InfuSystem was not involved in Round 1 nor
Round 2 of Competitive Bidding
CMS announced a Recompete of Round 1
competitive bidding on April 17th
External infusion pumps/supplies added as a
new product category
A supplier must bid on all items within the
product category to have its RFP considered
Recompete covers 9 Metropolitan Statistical
Areas (MSAs)
Competitive Bidding Overview
InfuSystem’s Response to Competitive Bidding
InfuSystem has engaged consultants and industry
professionals to discuss directly with CMS, advise
on positioning the Company for potential
regulatory changes, and facilitate potential
strategic partnership opportunities
InfuSystem was awarded contracts in all 9 MSAs
with average cuts of ~21% for our category per
CMS. 1 of 3 National Vendors to receive
contracts in all 9 markets.
“Competitive environment will vary in accordance
with the level of cuts by CMS”
CMS Competitive Bidding “Target”
Timetable
CMS will institute some form of competitive
CMS will institute some form of competitive
bidding nationwide by January 2016.
bidding nationwide by January 2016.
CMS began the pre-
bidding supplier
awareness program
CMS announced bidding
schedule, start bidder
education and begin a
bidder registration period
Bid window
opens
Current Round 1 bid
contracts expire
CMS announces Round
1 Recompete bid
results –
INFU impact
$250K annually
Bid window
closes
Implementation of
Round 1 bid contracts
and prices


Quarterly Financial History
Basic EPS


Detailed Historical P&L
(000's)
12/31/09
12/31/10
12/31/11
12/31/12
12/31/13
9M 2013
9M 2014
Net revenues:
Rentals
46,795
$        
53,471
$        
55,962
$        
41,556
         
44,150
         
Product sales
7,842
           
5,357
           
6,318
           
3,547
           
6,077
           
Net revenues:
38,964
         
47,229
         
54,637
         
58,828
         
62,280
         
45,103
         
50,227
         
Cost of Revenues:
Product, service and supply costs
6,200
           
7,730
           
9,128
           
9,165
           
11,274
         
8,174
           
9,024
           
Pump depreciation and loss on disposal
4,127
           
5,954
           
10,154
         
6,752
           
7,327
           
4,836
           
5,474
           
Gross Profit
28,637
         
33,545
         
35,355
         
42,911
         
43,679
         
32,093
         
35,729
         
Provision for doubtful accounts
4,006
           
4,515
           
4,099
           
5,251
           
6,534
           
4,782
           
4,811
           
Amortization of intangibles
1,827
           
2,259
           
2,662
           
2,734
           
2,618
           
1,972
           
1,876
           
Asset impairment charges
0
                    
0
                    
67,592
         
0
                    
0
                    
0
                    
0
                    
Selling and marketing
5,258
           
7,087
           
9,371
           
9,864
           
9,658
           
7,281
           
7,762
           
General and administrative
12,218
         
20,622
         
17,987
         
23,062
         
18,973
         
14,622
         
14,723
         
Operating income profit/(loss)
5,328
           
(938)
             
(66,356)
       
2,000
           
5,896
           
3,436
           
6,557
           
Total other gain/(loss)
(3,577)
          
(2,285)
          
(2,221)
          
(4,152)
          
(3,196)
          
(2,307)
          
(2,329)
          
Profit/(loss) before income taxes
1,751
           
(3,223)
          
(68,577)
       
(2,152)
          
2,700
           
1,129
           
4,228
           
Income tax benefit/(expense)
(977)
             
1,371
           
23,134
         
663
               
(1,031)
          
(324)
             
(1,907)
          
Net income/(loss)
774
$              
(1,852)
$         
(45,443)
$       
(1,489)
$         
1,669
$          
805
$              
2,321
$          
EBITDA
11,199
$        
7,745
$          
(57,336)
$       
9,590
$          
14,230
$        
9,747
$          
11,054
$        
EBITDA (ex. Impairment charges)
11,199
$        
7,745
$          
10,256
$        
9,590
$          
14,230
$        
9,747
$          
11,054
$        
Adjusted EBITDA
N/A
               
N/A
               
10,256
$        
13,126
$        
15,954
$        
11,271
$        
11,471
$        


Detailed Historical BS
(000's)
12/31/09
12/31/10
12/31/11
12/31/12
12/31/13
6/30/14
9/30/14
ASSETS
Current Assets:
Cash and cash equivalents
7,750
$          
5,014
$          
799
$              
2,326
$          
1,138
$          
1,041
$          
1,902
$          
Accounts receivable - total, net of allowance
5,517
           
6,679
           
7,448
           
8,511
           
10,697
         
10,768
         
11,505
         
Inventory
925
               
1,699
           
1,309
           
1,339
           
1,234
           
1,485
           
1,589
           
Prepaid expenses and other current assets
395
               
750
               
934
               
684
               
518
               
712
               
621
               
Deferred income taxes
125
               
1,147
           
682
               
1,971
           
2,296
           
2,296
           
2,296
           
Total Current Assets
14,712
         
15,289
         
11,172
         
14,831
         
15,883
         
16,302
         
17,913
         
Total PP&E and Medical Equipment
13,499
         
16,672
         
17,672
         
16,564
         
18,974
         
20,017
         
22,397
         
Deferred debt issuance costs, net
781
               
658
               
421
               
2,362
           
1,817
           
1,505
           
1,349
           
Total Goodwill and Intangible assets, net
85,491
         
97,344
         
28,221
         
25,541
         
24,182
         
24,287
         
24,461
         
Deferred income taxes
0
                    
0
                    
18,187
         
17,806
         
16,300
         
15,376
         
14,696
         
Other assets
207
               
401
               
590
               
419
               
217
               
248
               
208
               
Total Assets
114,690
$      
130,364
$      
76,263
$        
77,523
$        
77,373
$        
77,735
$        
81,024
$        
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable - total
1,306
$          
2,016
$          
4,063
$          
2,144
$          
4,736
$          
4,101
$          
4,570
$          
Accrued expenses and other
1,573
           
4,631
           
2,235
           
4,098
           
3,187
           
2,573
           
3,303
           
Derivative liabilities
2,670
           
183
               
258
               
0
                    
0
                    
0
                    
0
                    
Current portion of long-term debt
5,501
           
5,551
           
6,576
           
3,953
           
5,118
           
3,871
           
4,238
           
Total Current Liabilities
11,050
         
12,381
         
13,132
         
10,195
         
13,041
         
10,545
         
12,111
         
Long-term debt, net of current portion
18,640
         
26,646
         
22,551
         
27,315
         
21,609
         
22,829
         
23,631
         
Deferred income taxes
3,314
           
5,788
           
0
                    
0
                    
0
                    
0
                    
0
                    
Other liabilities
221
               
406
               
415
               
0
                    
0
                    
0
                    
0
                    
Total Liabilities
33,225
$        
45,221
$        
36,098
$        
37,510
$        
34,650
$        
33,374
$        
35,742
$        
Total Stockholders' Equity
81,465
$        
85,143
$        
40,165
$        
40,013
$        
42,723
$        
44,361
$        
45,282
$        
Total Liabilities and Equity
114,690
$      
130,364
$      
76,263
$        
77,523
$        
77,373
$        
77,735
$        
81,024
$        
Total Debt
24,141
$        
32,197
$        
29,127
$        
31,268
$        
26,727
$        
26,700
$        
27,869
$        
Net Debt
16,391
$        
27,183
$        
28,328
$        
28,942
$        
25,589
$        
25,659
$        
25,967
$        


Comparison to Other Infusion Companies
Stock Comparison
As of 11/20/14
BioScrip
Infu
Stock Price
$           5.99
2.85
52 Week hi
$           9.05
4.50
52 Week lo
$           5.44
1.70
Average Volume
1,000,850
174,194
In $ millions
Market Cap
$411.1m
$63.3m
P/E Ratio
(trailing)
N/A
20.29x
P/E Ratio
(forward)
75.12x
8.82x
Enterprise Value
$821.4m
$89.5m
Revenues (ttm)
$1,030m
$60.8m
Net Income (ttm)
$(93.6)m
$3.18m
EBITDA (ttm)
$(3.5)m
$16.7m
EBITDA Margin (% of rev)
N/A
27.4%
EV / EBITDA
N/A
5.4x
EBITDA Anlayst (FY2014)
$55.0m
17.4
EV / EBITDA
14.9x
5.1x
Stock Comparison
Source: Yahoo Finance
INFU has no direct small DME
niche public company comp. 
One often mentioned is
BioScrip Inc. (BIOS), but like
most other potential comps it is
broadly diversified beyond the
infusion sector.